SCHEMBL1361414

SCHEMBL1361414

COc1ccccc1OCCCc1oc(N(C)C)nc1-c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.38
MAPT P10636 5/20 0.38
DHPS P49366 2/20 0.38
GAA P10253 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 4/20 0.38
THRB P10828 1/20 0.38
MAPK1 P28482 3/20 0.38
TP53 P04637 2/20 0.38
ALOX15 P16050 1/20 0.38
L3MBTL1 Q9Y468 6/20 0.37
HPGD P15428 1/20 0.37
GCGR P47871 1/20 0.36
TDP1 Q9NUW8 3/20 0.36
POLB P06746 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1362813 0.88 DHPS (0.41) TSHRMAPTDHPSGAAHSD17B10
SCHEMBL1363172 0.88 MAOB (0.40) TSHRMAPTDHPSGAAHSD17B10
SCHEMBL1361698 0.86 MAPT (0.41) TSHRMAPTDHPSGAAHSD17B10
SCHEMBL1361665 0.79 GCGR (0.38) TSHRMAPTDHPSGAAHSD17B10
SCHEMBL1361404 0.78 L3MBTL1 (0.36) TSHRMAPTDHPSGAAHSD17B10
SCHEMBL1362462 0.78 L3MBTL1 (0.38) TSHRMAPTDHPSGAAHSD17B10
SCHEMBL1360126 0.78 DHPS (0.41) TSHRMAPTDHPSGAAHSD17B10
SCHEMBL1361683 0.78 SLC2A1 (0.44) TSHRMAPTGAAHSD17B10ALDH1A1
SCHEMBL1362416 0.77 PTGDR2 (0.45) TSHRMAPTDHPSGAAHSD17B10
SCHEMBL962882 0.77 MAPT (0.36) TSHRMAPTDHPSGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 US disclosed
EP-1206472-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT Takeda Chemical Industries, Ltd. (JP) 2002-05-22 EP disclosed
WO-2001014372-A2 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 TSHR 196/4885MAPT 3908/4885DHPS 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.